Skeletal Aging Patterns and Fracture Risk Prediction: A Comprehensive Clinical Review

Abstract

Skeletal aging is a progressive and multifactorial process characterized by changes in bone mass, microarchitecture, and strength, significantly impacting fracture risk, especially in older adults. This review synthesizes current evidence on the clinical patterns of skeletal aging, underlying mechanisms, and strategies for fracture risk prediction, integrating guideline-based recommendations and emerging therapeutic approaches to aid clinicians in optimizing patient care.

Introduction

As global life expectancy rises, the burden of age-related skeletal disorders such as osteoporosis and fragility fractures increases correspondingly. Skeletal aging encompasses a continuum of structural and metabolic changes that compromise bone quality and integrity, culminating in elevated fracture susceptibility. Understanding the interplay between bone biology, clinical risk factors, and predictive models is essential for healthcare professionals to mitigate morbidity and mortality associated with skeletal aging. This review aims to provide an in-depth appraisal of skeletal aging patterns, fracture risk assessment, and evidence-based management strategies for clinical practice.

Epidemiology / Disease Burden

Osteoporotic fractures represent a significant public health challenge, with an estimated 8.9 million fractures annually worldwide. The incidence rises exponentially with age, particularly among postmenopausal women and elderly men. In the United States, approximately 50% of women and 20% of men over 50 will experience an osteoporotic fracture in their lifetime. These fractures, especially hip and vertebral, result in increased mortality, substantial healthcare costs, and diminished quality of life. The aging population is projected to double the prevalence of osteoporosis and related fractures by 2040, emphasizing the need for effective prevention and management strategies.

Pathophysiology

Skeletal aging is driven by an imbalance between bone resorption and formation, influenced by declining sex steroids, increased oxidative stress, and altered cellular signaling. The reduction in osteoblast activity and enhanced osteoclast-mediated bone resorption result in net bone loss and deterioration of microarchitecture. Age-associated changes in the bone marrow microenvironment, including increased adipogenesis and inflammatory cytokine production, further impair bone remodeling. Additionally, decreased renal function and vitamin D synthesis contribute to secondary hyperparathyroidism, exacerbating bone loss. The cumulative effect is reduced bone strength and increased propensity for fragility fractures, even with minimal trauma.

Risk Factors

Fracture risk is multifactorial. Non-modifiable risk factors include advanced age, female sex, family history of osteoporosis, and prior fracture history. Modifiable factors encompass low body mass index, smoking, excessive alcohol intake, physical inactivity, and poor nutrition, particularly calcium and vitamin D deficiency. Comorbidities such as rheumatoid arthritis, diabetes, chronic kidney disease, and use of glucocorticoids or other bone-depleting medications further augment risk. Importantly, recent evidence highlights the significance of falls as a proximate risk factor, underscoring the interrelationship between skeletal and neuromuscular aging.

Clinical Features

Skeletal aging is often insidious and asymptomatic until a fracture occurs. Clinical hallmarks include loss of height, kyphosis, and increased susceptibility to low-energy fractures, most commonly of the vertebrae, hip, and distal radius. Vertebral fractures may present with acute back pain, but many are clinically silent and detected only through imaging. Hip fractures are associated with acute pain, immobility, and high short-term mortality. Chronic sequelae include persistent pain, functional impairment, and loss of independence, particularly in frail elderly populations.

Diagnosis

Diagnosis of skeletal aging and fracture risk assessment relies on a combination of clinical evaluation, imaging, and risk prediction tools. Bone mineral density (BMD) measurement by dual-energy X-ray absorptiometry (DXA) remains the gold standard for diagnosing osteoporosis. However, BMD alone does not capture alterations in bone quality or predict all fractures. The FRAX tool integrates clinical risk factors with or without BMD to estimate 10-year probability of hip and major osteoporotic fractures. Advanced imaging modalities such as trabecular bone score (TBS), high-resolution peripheral quantitative computed tomography (HR-pQCT), and vertebral fracture assessment (VFA) provide further insight into bone microarchitecture and fracture risk beyond BMD.

Treatment & Management

Management of skeletal aging focuses on fracture prevention through lifestyle modification, pharmacotherapy, and fall reduction. Lifestyle interventions include adequate intake of calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day), weight-bearing exercise, smoking cessation, and moderation of alcohol consumption. Pharmacologic options for high-risk individuals encompass antiresorptive agents (bisphosphonates, denosumab) and anabolic therapies (teriparatide, abaloparatide, romosozumab). Secondary causes of bone loss, such as endocrinopathies and medication-induced osteoporosis, should be identified and treated accordingly. Fall risk assessment and interventions, including balance training and home safety modifications, are integral components of comprehensive management.

Recent Advances / Emerging Therapies

Recent advances in the understanding of bone biology have led to the development of novel therapeutics targeting the Wnt signaling pathway, sclerostin inhibition, and selective estrogen receptor modulators. Romosozumab, a monoclonal antibody against sclerostin, has demonstrated superior efficacy in increasing BMD and reducing vertebral and clinical fractures in high-risk populations. The role of bone turnover markers in monitoring treatment response and optimizing therapy is under active investigation. Artificial intelligence and machine learning algorithms are being integrated into imaging and clinical risk prediction, enhancing individualized fracture risk assessment. Additionally, strategies targeting sarcopenia and frailty are being explored to address the neuromusculoskeletal interface in fracture prevention.

Guideline Recommendations

Major guidelines, including those from the American College of Physicians, National Osteoporosis Foundation, and International Osteoporosis Foundation, recommend risk-based screening for osteoporosis in women over 65 and men over 70, or earlier in individuals with risk factors. Pharmacotherapy is advised for patients with fragility fractures, osteoporosis on DXA (T-score \u2264 -2.5), or high FRAX probability. Duration and choice of therapy should be individualized based on fracture risk, comorbidities, and patient preferences. Periodic reassessment of BMD, fall risk, and adherence to lifestyle measures is essential for optimal long-term outcomes.

Conclusion

Skeletal aging is a complex process with significant clinical implications for fracture risk and patient outcomes. A nuanced understanding of its pathophysiology, risk factors, and predictive tools is vital for effective prevention and management. Ongoing research and emerging therapies are expanding the armamentarium for clinicians, while guideline-based, individualized care remains the cornerstone of reducing disease burden. Proactive risk assessment and multidisciplinary interventions are critical in addressing the challenges posed by skeletal aging and improving quality of life for aging populations.